Of late, more and more studies are being carried out to explore the anti-tumour activity of mifepristone. As Rose and Barnea1 reported, mifepristone can inhibit the growth of cultured ovarian carcinoma cells. The role of mifepristone in cis-diamminedichloroplatinum (CDDP) and taxol resistant ovarian carcinoma was found in Rocereto and colleagues' study.2 The purpose of this study was to examine the effect of mifepristone on the growth and CDDP-sensitivity of CDDP-resistant human ovarian carcinoma cells and give an experimental basis for the treatment with mifepristone of refractory ovarian carcinoma.